NRx Pharmaceuticals: FDA Nod for the Only Preservative-Free Ketamine Turns a Shortage Play Commercial

NRx is a commercial-stage biopharmaceutical company targeting depression, PTSD and suicidality. Revenue today — $1.1M in Q2 2026 — comes from its Hope Therapeutics interventional-psychiatry clinics. The newly approved Preservative-Free Ketamine adds the second engine: U.S.-manufactured generic ketamine injection, produced on high-volume blow-fill-seal lines at Nephron Pharmaceuticals in West Columbia, South Carolina, free of the benzethonium chloride preservative carried by every legacy formulation.

The strategy is vertically coherent. The clinics create treating-physician relationships and real-world data; the ANDA supplies the drug those clinics and thousands of hospitals use; and the planned NRX-100 NDA seeks FDA approval of IV ketamine for depression and suicidality using real-world evidence from more than 65,000 patients — a pathway that could make NRx the first company with an on-label psychiatric ketamine indication in 2027.

Margins on a shortage-listed generic with committed domestic capacity should exceed typical ANDA economics while the shortage persists, and non-dilutive funding layers on top: DARPA selected NRx as prime contractor for the SPARC-TMS Phase 2/3 trial of NRX-101 with robotic TMS, anticipated to deliver more than $11.5 million of non-dilutive funding, subject to contracting.

Full-Year Results

First-Half 2026 Progression

Quarterly Detail

Balance Sheet Snapshot

Guidance: management states current cash, anticipated clinic revenue and the at-the-market facility fund operations for at least one year; commercial launch targeted in 2026 with 5 million launch doses; NRX-100 NDA aimed at 2027 approval.

NRx occupies two niches: generic sterile injectables, where the incumbent ANDA holders' exits created the shortage it now attacks, and interventional psychiatry, where rapid-acting antidepressants compete for the same treatment-resistant patients.

• Johnson & Johnson (JNJ): Spravato (esketamine nasal spray) is the only FDA-approved rapid-acting antidepressant for treatment-resistant depression, with a franchise exceeding $1B in sales — but it is clinic-bound and far more expensive than generic IV ketamine.
• Hikma Pharmaceuticals (HIK.L): One of the largest U.S. generic injectable makers and an incumbent ketamine supplier; could re-enter aggressively once shortage pricing normalizes.
• Viatris (VTRS): A major ANDA holder with deep hospital distribution; the primary competitive threat if the shortage eases.
• Sage Therapeutics (SAGE): Zurzuvae (zuranolone) offers oral rapid relief in postpartum depression — a different mechanism contesting the same rapid-acting positioning.
• Compass Pathways (CMPS): Phase 3 psilocybin therapy; the other interventional-psychiatry challenger vying for treatment-resistant depression budgets.

Moats:

1. The only FDA-approved preservative-free ketamine for the U.S. market, against formulations carrying a preservative not recognized as safe.
2. Five million launch doses of manufactured supply plus 1 million units per month of domestic blow-fill-seal capacity at Nephron.
3. A real-world evidence base of more than 65,000 patients positioned to support the NRX-100 depression NDA.

1. Q4 2026: labeling and initial hospital and clinic supply agreements following the October 30 approval, converting the 5-million-dose launch stock into booked revenue.
2. November 16, 2026 (estimated): Q3 2026 results with first commentary on launch economics, pricing and the Nephron production ramp.
3. 2027: NRX-100 NDA progress for IV ketamine in depression and suicidality using real-world evidence from more than 65,000 patients.
4. Near term: conversion of the DARPA SPARC-TMS prime-contractor selection into contracted non-dilutive funding exceeding $11.5M.
5. Ongoing: production ramp toward 1 million units per month and any FDA shortage-list developments that further tighten domestic supply.